• Japanese
  • Korean
  • Chinese
Cover Image

The CNS Market Outlook to 2016

Abstract

Introduction

This report provides comprehensive coverage of the global CNS market, incorporating disease overview, epidemiological analyses of the major indications, and market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading CNS brands are assessed and five of the market' s leading players are profiled.

Features and benefits

  • Assess the forecast epidemiology and development of the CNS disorders across the 7MM.
  • Analyze the dynamics of the global CNS market and understand the impact of key R&D events, market trends, and issues.
  • Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
  • Predict revenues for major currently marketed and pipeline CNS products over from 2010 to 2016.
  • Develop strategies for success in the future CNS market.

Highlights

Antipsychotics were the largest CNS drug class with $24.2bn sales, a 33.9% share of the market in 2010. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016.

Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patents and safeguard revenue streams. Companies have also begun to manufacture and market generic versions of their products.

Of the indications in the CNS category, Alzheimer' s disease (AD) represents the main area of R&D interest for pharmaceutical companies, with an estimated 288 compounds in various stages of development.

Your key questions answered

  • What are the drivers and resistors of the CNS market worldwide?
  • What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the CNS market?
  • What is the forecast commercial potential of the most promising compounds in clinical development?
  • Who were the leading players in the global CNS market in 2010?
  • How have recent launches from companies such as Allergan, P&G, GSK, Eisai, and Novartis performed?

Table of Contents

About the author

  • Disclaimer

EXECUTIVE SUMMARY

  • Overview and epidemiology of CNS disorders
  • Industry structure and market dynamics
  • Pipeline analysis
  • Competitive landscape

Overview and epidemiology of CNS disorders

  • Summary
  • Introduction
    • Major depressive disorder (MDD)
    • Epilepsy
    • Schizophrenia
    • Alzheimer' s disease
    • Parkinson' s disease
    • Migraine
    • Insomnia
    • Attention-deficit hyperactivity disorder

Industry structure and market dynamics

  • Summary
  • Introduction
  • Global CNS market
    • Key events
    • Market drivers
    • Market challenges
  • Leading CNS brands
  • Market analysis by drug class
    • Antipsychotics
    • Antidepressants
    • Anti-epileptics
    • Alzheimer' s disease
    • Psychostimulants
    • Parkinson' s disease
    • Hypnotic/sedatives
    • Anti-migraine drugs
  • Genericization in the CNS market
  • Global CNS sales forecast

Pipeline analysis

  • Summary
  • Introduction
  • Key trends in R&D
    • Disease modifying therapies hold promise in Alzheimer' s disease
    • Anti-migraine market sees newer therapies after many years
    • Novel drugs with differentiated clinical profiles represent a sizeable market opportunity
    • SSRI generics and branded SNRIs are changing the depression landscape
    • Label expansions of antidepressants provide a significant opportunity for growth
    • Combination products hold potential in CNS market
  • CNS disorders pipeline
    • Key products under major CNS disorders
  • Leading drugs in development
    • Silenor (doxepin hydrochloride) - P&G/Somaxon Pharmaceuticals
    • Botox (onabotulinumtoxin-A) - Allergan
    • Potiga/Trobalt (retigabine/ezogabine) - GSK/Valeant Pharmaceuticals
    • Stedesa/Zebinix (eslicarbazepine acetate) - Sepracor/Eisai/Bial Group
    • Valdoxan/Thymanax/AGO178 (agomelatine) - Novartis and Servier
    • Latuda (lurasidone) - Dainippon Sumitomo
    • Levadex (dihydroergotamine mesylate) - MAP Pharmaceuticals/Allergan
    • Bapineuzumab (AAB-001) - Elan/J&J/Pfizer
    • Solanezumab (LY2062430) - Eli Lilly
    • Telcagepant (MK-0974) - Merck
    • RG1678/RO4917838 - Roche/Chugai
    • TC-5214 (S-mecamylamine) - AstraZeneca/Targacept
    • LY2216684/NERI (edivoxetine) - Eli Lilly
    • MK-4305 - Merck & Co.
    • IPX066 (Carbidopa/levodopa) - GSK and Impax
    • Pipeline forecast of leading drugs in development

Competitive landscape

  • Summary
  • Introduction
  • Eli Lilly
    • Overview
    • Financial performance
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
  • Pfizer
    • Overview
    • Financial performance
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
  • AstraZeneca
    • Overview
    • Financial performance
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
  • Johnson & Johnson
    • Overview
    • Financial performance
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
  • GlaxoSmithKline
    • Overview
    • Financial performance
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis

Appendix

  • Scope
  • Methodology
    • Market size methodology
    • Epidemiology
    • Market forecast
  • Glossary/Abbreviations
  • Bibliography/References
    • Prevalence of MDD
    • Prevalence of epilepsy
    • Prevalence of schizophrenia
    • Prevalence of Alzheimer' s disease
    • Prevalence of Parkinson' s disease
    • Prevalence of migraine
    • Prevalence of insomnia
    • Prevalence of ADHD
    • Others

TABLES

  • Table: Prevalence of MDD in the 7MM, 2010
  • Table: Forecast epidemiology of MDD in the 7MM, 2010
  • Table: Prevalence of epilepsy in the 7MM, 2010
  • Table: Forecast epidemiology of epilepsy in the 7MM, 2010
  • Table: Prevalence of schizophrenia in the 7MM, 2010
  • Table: Forecast epidemiology of schizophrenia in the 7MM, 2010
  • Table: Prevalence of Alzheimer' s disease in the 7MM, 2010
  • Table: Forecast epidemiology of Alzheimer' s in the 7MM, 2010
  • Table: Prevalence of Parkinson' s disease in the 7MM, 2010
  • Table: Forecast epidemiology of Parkinson' s disease in the 7MM, 2010
  • Table: Prevalence of migraine in the 7MM, 2010
  • Table: Forecast epidemiology of migraine in the 7MM, 2010
  • Table: Prevalence of insomnia in the 7MM, 2010
  • Table: Forecast epidemiology of insomnia in the 7MM, 2010
  • Table: Prevalence of ADHD in adults in the 7MM, 2010
  • Table: Prevalence of ADHD in children in the 7MM, 2010
  • Table: Forecast epidemiology of ADHD in adults in the 7MM, 2010
  • Table: Forecast epidemiology of ADHD in children in the 7MM, 2010
  • Table: Regional performance of CNS market, 2006 - 2010
  • Table: Leading 10 CNS products, 2010
  • Table: Sales performance of various CNS drug class, 2010
  • Table: Leading antipsychotic products, 2010
  • Table: Leading antidepressant products, 2010
  • Table: Leading anti-epileptics products, 2010
  • Table: Leading anti-Alzheimer' s products, 2010
  • Table: Leading psychostimulants products, 2010
  • Table: Leading anti-Parkinson' s products, 2010
  • Table: Leading hypnotic/sedative drugs, 2010
  • Table: Leading anti-migraine products, 2010
  • Table: Patent expirations of key CNS brands
  • Table: Forecast sales of CNS drug classes ($m), 2010 - 16
  • Table: CNS market forecast for Top 10 brands ($m), 2010 - 16
  • Table: Global CNS pipeline by indication and stage of development, May 2011
  • Table: An overview of Silenor
  • Table: An overview of Botox
  • Table: An overview of Potiga/Trobalt
  • Table: An overview of Stedesa
  • Table: An overview of Valdoxan/Thymanax
  • Table: An overview of lurasidone
  • Table: An overview of Levadex
  • Table: Clinical trial data points for Levadex
  • Table: An overview of bapineuzumab
  • Table: An overview of solanezumab
  • Table: An overview of telcagepant
  • Table: An overview of RG1678/RO4917838
  • Table: An overview of TC-5214
  • Table: An overview of LY2216684
  • Table: An overview of MK-4305
  • Table: An overview of IPX066
  • Table: Sales forecast for leading drugs in development ($m), 2010 - 16
  • Table: Leading players of the CNS market 2010*
  • Table: Leading CNS brands of Lilly , 2010
  • Table: Lilly' s CNS R&D product pipeline, January 2011
  • Table: Leading CNS brands of Pfizer , 2010
  • Table: Pfizer' s CNS R&D product pipeline, May 2011
  • Table: Leading CNS brands of AstraZeneca , 2010
  • Table: AstraZeneca ' s CNS R&D product pipeline , January 2011
  • Table: Leading CNS brands of J&J , 2010
  • Table: J&J' s CNS R&D product pipeline, April 2011
  • Table: Leading CNS brands of GSK , 2010
  • Table: GSK' s CNS R&D product pipeline, February 2011

FIGURES

  • Figure: Schizophrenia: classification of symptoms
  • Figure: Typical treatment patterns in the treatment of schizophrenia
  • Figure: Different stages of Alzheimer' s disease
  • Figure: Typical treatment patterns in the treatment of migraine
  • Figure: Selected late-stage, filed and recently launched CNS drugs
Show More
Pricing